vopikitug
Term · Oncology and biomedicine · MLC-T-ONC-017532
A monoclonal antibody against CD25 (IL-2R alpha), with potential antineoplastic activity. Upon administration, vopikitug targets and binds to CD25 expressed on tumor-infiltrating regulatory T (Treg) cells. This may deplete Treg cells and prevent immunosuppression, thereby enhancing anti-tumor immune responses. CD25, the alpha chain of the interleukin (IL)-2 receptor, is highly expressed on Treg cells but not on effector T (Teff) cells in tumors.
| Identifier | MLC-T-ONC-017532 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | anti-CD25 monoclonal antibody RG6292; T-regulatory cell-depleting antibody RO7296682; anti-CD25 monoclonal antibody RO7296682 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-017532",
"term": "vopikitug",
"field": "Oncology and biomedicine",
"definition": "A monoclonal antibody against CD25 (IL-2R alpha), with potential antineoplastic activity. Upon administration, vopikitug targets and binds to CD25 expressed on tumor-infiltrating regulatory T (Treg) cells. This may deplete Treg cells and prevent immunosuppression, thereby enhancing anti-tumor immune responses. CD25, the alpha chain of the interleukin (IL)-2 receptor, is highly expressed on Treg cells but not on effector T (Teff) cells in tumors.",
"synonyms": [
"anti-CD25 monoclonal antibody RG6292",
"T-regulatory cell-depleting antibody RO7296682",
"anti-CD25 monoclonal antibody RO7296682"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/vopikitug/"
}
Record 17,337 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.